Wegovy, Zepbound and Novo Nordisk
Digest more
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top.
GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress on Obesity comparing new-generation weight-loss drugs
President Trump announced an executive order to significantly reduce U.S. drug prices, aiming to align with costs in other nations. Eli Lilly's Zepbound drug outperforms Wegovy in a weight-loss trial.